MedTrace Logo

Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer

NCT00193934 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 109

Last updated 2017-07-12

No results posted yet for this study

Summary

The researchers propose that it may be corpus invasion, rather than tumour volume per se, which is one of the important determinants of ultimate outcome in cervix cancer. The aim of the proposed prospective, multicentre study, is to confirm the results of our retrospective studies, specifically that corpus invasion or tumour volume or both contribute important prognostic information over and above that provided by the currently used International Federation of Gynecology and Obstetrics (FIGO) staging system. A successful outcome would have important implications for the staging, and management as well as the biologic understanding of the behaviour of cervical cancer.

Conditions

  • Cancer of the Uterine Cervix

Sponsors & Collaborators

  • Peter MacCallum Cancer Centre, Australia

    collaborator OTHER

  • Trans Tasman Radiation Oncology Group

    lead OTHER

Principal Investigators

  • Gerard Adams · Oceania Oncology

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2014-05-31
Completion
2014-05-15

Countries

  • United States
  • Australia
  • India
  • New Zealand
  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00193934 on ClinicalTrials.gov